Healthcare / Medical DevicesHelsinki
$8.75
+0.13 (+1.51%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 16%
FCF escenarios
weak_data · normalized FCF $-37349.90 · quality 34.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
29/100
D
Piotroski
7/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$63M
P/E
109.4x
↑EV/EBITDA
35.0x
↑ROE
13.7%
↑Gross Margin
90.3%
↑Debt/Equity
0.99
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+4.8%
FCF CAGR
—
FCF margin
-0.3%
FCF / Net income
-0.07x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $11.0M · net income $573198.3 · FCF $-37349.9
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $11.0M | $11.0M | $8.7M | $7.2M | $9.5M |
| Net Income | $573198.28 | $573198.28 | $-892288.29 | $-1.3M | $1.3M |
| EBITDA | $1.8M | $1.8M | $456403.75 | $-511273.84 | $1.9M |
| EPS | 0.08 | 0.08 | -0.13 | -0.20 | 0.18 |
| Gross Margin | 90.3% | 90.3% | 95.9% | 96.4% | 99.9% |
| Operating Margin | 5.8% | 5.8% | -6.1% | -16.5% | 8.8% |
| Net Margin | 5.2% | 5.2% | -10.2% | -18.3% | 13.7% |
| Balance Sheet | |||||
| Debt/Equity | 0.99 | 0.99 | 1.45 | 1.56 | 0.86 |
| Current Ratio | 1.27 | 1.27 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-37349.90 | $-37349.90 | $175427.55 | $-3.8M | $-438092.67 |
| Returns | |||||
| ROE | 13.7% | 13.7% | -24.1% | -46.8% | 32.1% |
| Valuation | |||||
| P/E | 109.38 | 109.38 | — | — | 23.61 |
| EV/EBITDA | 35.03 | 35.03 | 131.11 | — | 16.04 |
| P/B | 14.99 | 14.99 | 15.77 | 6.32 | 7.58 |
| Growth & Yield | |||||
| Revenue Growth | 25.6% | 25.6% | 20.5% | -23.9% | — |
| EPS Growth | 161.5% | 161.5% | 35.0% | -211.1% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
113.3%
EPS terminal req.
$0.78
Spread vs growth
48.2%
5Y implied EPS CAGR
63.7%
EPS terminal req.
$0.94
Spread vs growth
97.9%
10Y implied EPS CAGR
34.2%
EPS terminal req.
$1.51
Spread vs growth
127.4%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+11.6%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.13 → 0.08
Residual
+11.6%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.